Ribociclib Succinate (LEE011): Selective CDK4/6 Inhibitor for Cancer Research

Executive Summary: Ribociclib succinate (CAS No. 1374639-75-4) is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, primarily indicated for research on HER2-positive metastatic breast cancer cell proliferation (Desai et al., 2024). It induces cell cycle arrest by targeting CDK4 and CDK6, key regulators of G1 to S phase transition [Tetramisolehclbio, 2023]. The compound displays moderate solubility in both simulated gastric (pH 1.2, 814.05 μg/mL) and intestinal (pH 6.5, 494.71 μg/mL) buffers, with minimal solubility loss on pH shift (Desai et al., 2024). Oral dosing at 600 mg/day is standard for research models, and co-administration with acid-reducing agents or food does not significantly alter its absorption or efficacy (Desai et al., 2024). APExBIO supplies Ribociclib succinate (SKU B1084) for research use only, with validated analytical methods exhibiting an LOD of 1.53 μg/mL and LOQ of 4.66 μg/mL [APExBIO Product Page].

Biological Rationale

Cell cycle progression is tightly regulated by cyclin-dependent kinases (CDKs), including CDK4 and CDK6, which form complexes with cyclins D1 and D3. Aberrant activation of the cyclin D-CDK4/6 axis is a hallmark of many cancers, notably HER2-positive metastatic breast cancer [CCT241533hydrochloride, 2023]. Inhibition of CDK4/6 disrupts phosphorylation of the retinoblastoma (Rb) protein, enforcing G1 cell cycle arrest and limiting proliferation [Tetramisolehclbio, 2023]. Ribociclib succinate (LEE011 succinate) is engineered for high selectivity and potency against CDK4/6, enabling precise dissection of cell cycle regulatory mechanisms in cancer biology research [Survivin.net, 2023].

Mechanism of Action of Ribociclib succinate

Ribociclib succinate binds selectively to the ATP-binding site of CDK4 and CDK6, inhibiting their kinase activity. This prevents phosphorylation of Rb protein, thereby blocking E2F transcription factor release and arresting cells in the G1 phase. In HER2-positive metastatic breast cancer models, this results in reduced tumor cell proliferation and increased apoptosis (Desai et al., 2024). The compound is classified as a cell cycle pathway inhibitor, with applications in cell proliferation assays and apoptosis studies. Ribociclib displays moderate aqueous solubility (e.g., 814.05 μg/mL at pH 1.2; 463.20 μg/mL at pH 6.8) and is stable when stored at -20°C [APExBIO Product Page].

Evidence & Benchmarks

• Ribociclib succinate shows selective inhibition of CDK4/6, with no significant off-target activity against other CDK family members under standard assay conditions (Desai et al., 2024).
• In micro-dissolution experiments, solubility in simulated gastric fluid (pH 1.2) was measured at 814.05 μg/mL, while in intestinal fluid (pH 6.5–6.8), solubility ranged from 494.71 to 463.20 μg/mL (Desai et al., 2024).
• Co-administration with acid-reducing agents such as proton pump inhibitors does not significantly affect Ribociclib's solubility or absorption (Desai et al., 2024).
• The validated analytical method for Ribociclib succinate achieves an LOD of 1.53 μg/mL and LOQ of 4.66 μg/mL, with linear quantification from 0.1–150 μg/mL (Desai et al., 2024).
• Oral administration (600 mg/day as 200 mg film-coated tablets) enables effective exposure in preclinical and translational research models (Desai et al., 2024).

This article extends the scenario-driven applications described in "Solving Cell Cycle Research Challenges with LEE011 succinate" by providing new quantitative solubility and pharmacokinetic data under physiologically relevant conditions. It further clarifies and updates the mechanistic insights reviewed in "LEE011 succinate: A Highly Selective CDK4/6 Inhibitor for…" by linking recent analytical benchmarks and pH interaction studies.

Applications, Limits & Misconceptions

Ribociclib succinate is primarily used in cancer biology for dissecting cell cycle regulation, antineoplastic screening, and evaluating apoptosis via CDK4/6 inhibition. Its compatibility with endocrine and aromatase inhibitor combinations makes it an ideal tool for translational oncology [CCT241533hydrochloride, 2023]. The compound’s moderate solubility and pH-independence enhance its reliability in varied assay systems.

Common Pitfalls or Misconceptions

• Not a diagnostic or therapeutic agent: Ribociclib succinate supplied by APExBIO is strictly for research use and not approved for clinical or diagnostic purposes (APExBIO).
• Acid-reducing agents: Contrary to some weakly basic drugs, co-administration does not require dose adjustment due to negligible impact on solubility or absorption (Desai et al., 2024).
• Cell type specificity: Efficacy and cell cycle arrest are most pronounced in models with intact Rb pathways; loss-of-function Rb mutations may confer resistance ([CCT241533hydrochloride, 2023]).
• BCS class IV characteristics: While Ribociclib is a BCS class IV drug with low solubility and moderate permeability, validated protocols ensure analytical reliability within the specified linear range (Desai et al., 2024).
• Storage conditions: Compound integrity requires storage at -20°C; deviation may reduce potency (APExBIO).

Workflow Integration & Parameters

For cell proliferation and apoptosis assays, Ribociclib succinate is typically dissolved in DMSO and applied at concentrations aligned with its analytical linear range (0.1–150 μg/mL). The standard oral dose for in vivo models is 600 mg/day, administered as 200 mg tablets, compatible with both fasting and fed conditions (Desai et al., 2024). Solubility in simulated gastric and intestinal fluids supports reproducibility in pharmacokinetics studies. Analytical detection is robust, with an LOD of 1.53 μg/mL. APExBIO provides detailed protocols and validated product documentation for the B1084 kit (Ribociclib succinate product page).

For advanced protocol enhancements and troubleshooting, see "LEE011 Succinate: Precision CDK Inhibition for Cancer Research", which offers additional guidance on optimizing antineoplastic screening and cell cycle assays with LEE011 succinate. This complements the current article's emphasis on pH-robust solubility and validated analytical parameters.

Conclusion & Outlook

Ribociclib succinate (LEE011 succinate) stands as a highly selective and well-characterized CDK4/6 inhibitor for cancer research. Its moderate, pH-independent solubility, validated analytical detection, and compatibility with combination therapies make it a benchmark tool in cell cycle and translational oncology studies. Ongoing updates to analytical protocols and mechanistic insights will continue to enhance its value for biomedical researchers. For full specifications and ordering, refer to the APExBIO Ribociclib succinate (B1084) product page.